
Wolfgang Merkt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3883800/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of <scp>JAK</scp> Inhibition on the Induction of Proinflammatory <scp>HLA</scp> – <scp>DR</scp> + <scp>CD90</scp> + Rheumatoid Arthritis Synovial Fibroblasts by Interferon‵³. Arthritis and Rheumatology, 2022, 74, 441-452.	5.6	20
2	Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Annals of the Rheumatic Diseases, 2022, 81, 744-746.	0.9	5
3	Leflunomide in combination with JAK-inhibitors in the treatment of rheumatoid arthritis: a case series. Rheumatology, 2022, , .	1.9	1
4	Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides. BMC Immunology, 2021, 22, 26.	2.2	6
5	Myofibroblast fate plasticity in tissue repair and fibrosis: Deactivation, apoptosis, senescence and reprogramming. Wound Repair and Regeneration, 2021, 29, 678-691.	3.0	20
6	Senotherapeutics: Targeting senescence in idiopathic pulmonary fibrosis. Seminars in Cell and Developmental Biology, 2020, 101, 104-110.	5.0	64
7	Activation of natural killer cells by rituximab in granulomatosis with polyangiitis. Arthritis Research and Therapy, 2019, 21, 277.	3.5	7
8	Rituximab and Fcγ Receptors in Granulomatosis With Polyangiitis (Wegener's): Comment on the Article by Cartin eba et al. Arthritis and Rheumatology, 2017, 69, 1506-1507.	5.6	0
9	Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56dim natural killer cells. Arthritis Research and Therapy, 2016, 18, 204.	3.5	8
10	Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting. Arthritis Research and Therapy, 2016, 18, 206.	3.5	20
11	Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage. Arthritis Research and Therapy, 2015, 17, 337.	3.5	14